Ai Di Weixin, who submitted the form to the Hong Kong Stock Exchange, has any other research and development pipelines besides the new crown DNA vaccine?

In the mechanism equivalent test initiated by the researchers, the functional cure index of ADV311 was as high as 15.
4%, far exceeding other similar vaccines under development
.
The vaccine is expected to submit a new drug clinical trial (IND) application to CDE in 2022
.

In addition, Ai Diweixin also has 3 pre-clinical vaccine candidates.
Among them, ADV510 is a therapeutic candidate vaccine based on tumor virus antigens for the prevention and treatment of Merkel cell carcinoma; ADV520 is a tumor-related vaccine candidate.
Antigen, a therapeutic candidate vaccine for the treatment of tumors; and ADV610 is a novel antigen-based therapeutic candidate vaccine for the treatment of mutant tumors
.

 Ai Di Weixin's financing history

Ai Di Weixin has received a total of five rounds of investment in history, and made one acquisition (obtained 100% equity of Suzhou Siao Biotech), and its latest capital increase has a post-investment valuation of approximately RMB 3.
672 billion
.
Shareholders brought together a number of sophisticated investors, including Matrix Partners China, Fortune Wise, the National SME Development Fund, Hony investment
.

Ai Di Weixin's historical financing situation (source reference 1)

As a high-tech enterprise focusing on innovative vaccines, Ai Di Weixin has an innovative technology platform, a broad market space, and a product pipeline with leading research and development progress.
With the completion of the recent round of financing, the clinical research and industrialization of DNA vaccines It will further accelerate and move to a new level
.
I hope that with the help of capital, Ai Diweixin will bring the products under research to the market as soon as possible to benefit patients
.

   Reference source:

1.
Ai Di Weixin Prospectus;

2.
Ai Di Weixin's official website
.